In 870 patients aged 18-65 with mantle cell lymphoma, adding ASCT to ibrutinib-containing treatment did not improve 4-year failure-free survival (82% vs 81%; HR 0.86) after a median 54.9 months, but raised grade 3-5 haematological toxicity (54% vs 28%).
RCTn = 870
Dreyling et al. Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network